Pfizer Tries To Revitalize Obesity Portfolio With $5 Billion Matsera Deal

1. Pfizer acquires Metsera for $4.9 billion to enhance obesity treatments. 2. Metsera's pipeline includes promising therapies for cardiometabolic diseases. 3. Deal expected to close in Q4 2025, with milestone payments involved. 4. Acquisition positions Pfizer in a key growth area post danuglipron failure. 5. PFE stock rose 1.75% amid acquisition news, indicating positive market sentiment.